Research programme: HIV DNA vaccines - Inovio/IAVI

Drug Profile

Research programme: HIV DNA vaccines - Inovio/IAVI

Alternative Names: HIV DNA vaccines - Inovio/IAVI

Latest Information Update: 15 Oct 2012

Price : $50

At a glance

  • Originator Genetronics Inc
  • Developer Genetronics Inc; International AIDS Vaccine Initiative
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 15 Oct 2012 No development reported - Preclinical for HIV infections in USA (Intradermal)
  • 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals
  • 31 Mar 2007 Preclinical trials in HIV infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top